MedTrace Logo

Type 2 Diabetes Haptoglobin Phenotype and Vitamin E

NCT01113671 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2011-01-11

No results posted yet for this study

Summary

This is a biomarker exploratory study which is designed to investigate the function and oxidation of the high density lipoprotein (HDL) (the good cholesterol) in patients with type 2 diabetes mellitus treated with Vitamin E versus placebo and segregated by the type of the Haptoglobin protein they have in their blood.

Conditions

  • Diabetes Mellitus Type 2

Interventions

DRUG

Vitamin E (d-alpha-tocopheryl acetate)

100% natural source d-alpha-tocopheryl acetate in a soft gel cap

DRUG

Placebo

includes inactive Ingredients

Sponsors & Collaborators

  • Technion, Israel Institute of Technology

    lead OTHER

Principal Investigators

  • Shany Blum, MD PhD · Technion, Israel Institute of Technology

  • Andrew Levy, MD PhD · Technion, Israel Institute of Technology

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-07-31
Completion
2011-01-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01113671 on ClinicalTrials.gov